Johnson & Johnson announced on Tuesday its diluted earnings per share (EPS) jumped 172.3% in the fourth quarter of 2021 compared to the same period in 2020. Sales increased 10.4% annually, reaching $24.8 billion, while net earnings soared 172.5% to $4.7 billion.

Full-year EPS rose by 41.7% year-on-year to $7.81, while sales added 13.6% and amounted to $93.8 billion, and net earnings added 42.1% on a yearly basis and stood at $20.9 billion. The company adjusted its 2022 guidance, estimating operational sales growth of 7.7% and adjusted operational EPS growth of 9.2%.

J&J's shares dropped 1.52% in premarket trade following the earnings release.